Over 80% of the proteins that cause serious diseases, such as many types of cancer and neurodegenerative diseases, are considered undruggable with conventional drugs. Gleipnir Lífsmiðja is a biotechnology company that is tackling this problem with its unique SKÍRNIR screening platform. Instead of searching for the drug itself, SKÍRNIR uses synthetic biology in yeast cells to answer the first and most important question: Which two proteins should be „glued“ together to inactivate the disease protein?
This approach transforms drug discovery from an expensive and haphazard search to a targeted and systematic process. It saves pharmaceutical companies a lot of time in development work and significantly reduces risk and costs. Gleipnir Lífsmiðja's goal is to become a leading international partner in the discovery of new treatments and thus accelerate the development of so-called molecular glue drugs against diseases that have so far been considered incurable.
